Jerry Buysse
Researcher
research and development
Tricida
Russian Federation
Biography
Dr. Jerry Buysse has served as Chief Scientific Officer for three biopharmaceutical companies, focusing on the discovery and development of non-absorbed polymeric drugs for the treatment of metabolic, cardiovascular and renal diseases. As a scientist and co-founder, Dr. Buysse has helped to raise funding from venture capital and corporate partners that established Ilypsa (acquired by Amgen in 2007), Relypsa (IPO November 2013, NASDAQ: RLYP) and Tricida (launched in January, 2014). Dr. Buysse currently serves as Chief Scientific Officer & SVP at Tricida, a biopharmaceutical company developing therapies for the treatment of renal disease complications. Prior to Tricida, he was Chief Scientific Officer of Relypsa (2007 – 2013), guiding the team that discovered Relypsa’s lead product, patiromer, a non-absorbed potassium binder for the treatment of hyperkalemia. Other experience includes his role as Vice President of Research and Development at Ilypsa (2003 -2007), responsible for preclinical discovery and development that identified the phosphate binder bixalomer, currently marketed as Kiklin by Astellas. Dr. Buysse joined Ilypsa in 2003 following seven years at Microcide Pharmaceuticals (1996-2003) where he was Vice President of Discovery Biology, responsible for screening and lead discovery in Microcide’s antibacterial and antifungal programs. Dr. Buysse was a Senior Research Scientist at Pharmacia & Upjohn (1992-1996) and contributed to the preclinical discovery of linezolid (currently marketed as Zyvox by Pfizer). He was a National Research Council Fellow and Senior Research Microbiologist at the Walter Reed Army Institute of Research (1984-1992), working on bacterial pathogenesis topics in Shigella and Salmonella infections. Dr. Buysse received his BS in Microbiology at The University of Michigan, Ph.D. in Immunology and Microbiology from Wayne State University School of Medicine and completed postdoctoral studies at Tufts University School of Medicine.
Research Interest
molecular Biology, Medicine science
